ONE59

One59 is a Swiss biotechnology company focused on developing first-in-class therapies targeting cellular senescence and the tumor microenvironment. Spun out from the Institute of Oncology Research (IOR), the company leverages breakthrough discoveries regarding the role of myeloid-derived suppressor cells (MDSCs) in cancer progression. Its primary focus is on advanced prostate cancer, where it aims to neutralize the immunosuppressive effects of the senescence-associated secretory phenotype (SASP). By inhibiting specific pathways like CXCR2, One59 seeks to enhance the efficacy of existing treatments and provide new options for patients with therapy-resistant tumors. The company operates at the intersection of immunology and cancer biology to pioneer senomorphic therapeutic approaches.